Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Sponsor: University of Colorado, Denver
Summary
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.
Official title: A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Key Details
Gender
All
Age Range
65 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-04-01
Completion Date
2028-03
Last Updated
2026-04-08
Healthy Volunteers
Yes
Interventions
Psilocybin (Usona Institute)
Evaluate the safety and tolerability of psychedelic administration in two cohorts of healthy older adults. * Cohort 1a Psilocybin Moderate Dose: 2 doses of oral psilocybin (10mg and then 25mg) 30 days apart. * Cohort 1b Psilocybin High Dose: 2 doses of oral psilocybin (15mg and then 30mg) 30 days apart.
Locations (6)
University of California San Francisco (UCSF) Department of Neurology
San Francisco, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Emory University Brain Health Center
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
New York University Langone Health, Center for Psychedelic Medicine
New York, New York, United States